Oppenheimer Raises Humana Price Target to $475 on Strong Medicare Ratings

Key Facts

1Oppenheimer raised Humana's price target to $475 from $405, maintaining an 'Outperform' rating.

2Humana reported that 95% of its Medicare Advantage members are in plans rated at least four stars for 2027.

Oppenheimer raised Humana's price target to $475 from $405 while maintaining an 'Outperform' rating on the stock. Financial Modeling Prep reported that the upgrade follows Humana's announcement that 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027.

Humana closed at $387.12 on October 8, 2026, with the stock trading between a day low of $375.86 and a high of $399.19 during that session. The recovery in star ratings makes the company eligible for significant quality-related bonus payments and strengthens its competitive position in the health insurance market.